TLDR Tofacitinib may effectively treat folliculitis decalvans.
The case series documented the responsiveness of folliculitis decalvans to tofacitinib treatment. The study was conducted by Rebekka Jerjen and colleagues at Sinclair Dermatology in East Melbourne, Victoria, Australia. Although the article did not provide an abstract, it highlighted the potential effectiveness of tofacitinib, a Janus kinase inhibitor, in treating this chronic scalp condition characterized by inflammation and hair loss. The findings suggested that tofacitinib could be a promising therapeutic option for patients suffering from folliculitis decalvans, offering a new avenue for managing this challenging dermatological issue.
10 citations
,
October 2019 in “Australasian Journal of Dermatology” Secukinumab effectively treated a difficult case of folliculitis decalvans.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
159 citations
,
October 2015 in “Science Advances” Blocking JAK-STAT signaling can lead to hair growth.
43 citations
,
January 2015 in “Journal of Cutaneous Medicine and Surgery” Most patients improved with oral antibiotics, but some needed long-term treatment or had minimal response.
220 citations
,
June 2013 in “The Journal of Pathology” Lichen planopilaris may be an autoimmune disease causing hair loss due to immune system issues in hair follicles.
98 citations
,
May 2008 in “British Journal of Dermatology” There are many treatments for permanent hair loss disorders, but their effectiveness varies and there's no clear best option.
